M&A: Treeline goes public via reverse merger

Treeline Biosciences announced a definitive reverse-merger agreement with Standard BioTools, positioning the combined company to trade on Nasdaq under the TRLN ticker. Standard BioTools shareholders are expected to own about 16% of the new entity, while Treeline’s holders will own about 84%. Treeline plans to raise a longer runway, with the combined company expected to have more than $900 million in cash at closing.